Posts by: Iqra Mumal, MSc

Iqra Mumal, MSc

Iqra holds a MSc in Cellular and Molecular Medicine from the University of Ottawa in Ottawa, Canada. She also holds a BSc in Life Sciences from Queen’s University in Kingston, Canada. Currently, she is completing a PhD in Laboratory Medicine and Pathobiology from the University of Toronto in Toronto, Canada. Her research has ranged from across various disease areas including Alzheimer’s disease, myelodysplastic syndrome, bleeding disorders and rare pediatric brain tumors.

December 17, 2019December 17, 2019

Febrile Seizures After Vaccination May Indicate Dravet, Study Shows

News

Infants who develop febrile seizures a short time after being vaccinated and are positive for a disease-causing mutation in the SCN1A gene should be considered for a diagnosis of ... Read more

January 24, 2019January 24, 2019

Ketogenic Diet May Not Promote Neuropsychological Development in Dravet, Study Suggests

News

Contrary to what was previously believed, the ketogenic diet — a low-carbohydrate, high-fat diet— did not significantly promote cognition and neuropsychological development in children with Dravet syndrome over time, according to ... Read more

January 22, 2019January 22, 2019

For Caregivers of Dravet Patients, Emotional and Financial Impact High, Study Reports

News

Families caring for patients with Dravet syndrome experience significant emotional, social, and financial impact, according to a multinational study. This study also found that directs costs from non-seizure-related healthcare use ... Read more

August 30, 2018August 30, 2018

FDA Accepts New Drug Application for Nayzilam Nasal Spray for Acute Treatment of Seizures

News

The U.S. Food and Drug Administration has accepted a new drug application (NDA) for UCB’s Nayzilam (midazolam) nasal spray for the acute treatment of seizures including seizure clusters and acute ... Read more

August 9, 2018August 9, 2018

Compound from Spider Venom Reduces Seizure Susceptibility, Mortality in Dravet Syndrome Mice

News

A compound isolated from spider venom called Hm1a helps reduce seizure susceptibility and mortality in mice with Dravet syndrome, according to researchers. Their study, “Selective NaV1.1 activation rescues Dravet ... Read more

August 2, 2018August 2, 2018

Dravet Patients Responded Well to Treatment with Perampanel as Add-On Therapy

News

Perampanel, as an add-on therapy, efficiently reduced seizure rates in children with Dravet syndrome, a real-world study shows. The study, “Efficacy and tolerability of perampanel in children and adolescents ... Read more

July 17, 2018July 17, 2018

Phase 3 Trial Finds ZX008 Lowers Number and Frequency of Seizures in Dravet Patients, Zogenix Reports

News

Zogenix reported positive top-line results from a second confirmatory Phase 3 study investigating the use of ZX008 (low-dose fenfluramine hydrochloride) in treating children and young adults with Dravet syndrome, ... Read more

July 5, 2018August 17, 2018

Genetic Mosaicism May Contribute to Milder Clinical Symptoms in Dravet and Related Disorders

News

A phenomenon known as “genetic mosaicism” may contribute to milder symptoms in people with Dravet syndrome and related disorders, a new study shows. The study, “Mosaicism of de novo ... Read more

March 8, 2018March 8, 2018

Levetiracetam More Effective than Phenobarbital in Treating Seizures, Study Suggests

News

Levetiracetam (marketed as Keppra), an anti-epileptic therapy, is significantly more effective than phenobarbital medication in infants with epilepsy, a recent study found, which could have implications for patients with ... Read more